Hamburg, Germany
mo:re is a burgeoning player in the Biotechnology and Pharmaceutical sectors, ingeniously converging with Robotics to enhance research efficiencies. Founded in 2023 and headquartered in Germany, the company’s flagship product, MO:BOT, presents a revolutionary leap with its fully automated platform designed for 3D Cell Culture.
The platform's defining characteristics include comprehensive automation, built-in quality control, and the capability for regulatory-grade traceability. These features aim to significantly accelerate drug discovery processes while diminishing reliance on animal testing. By offering a truly integrated system, mo:re empowers researchers to produce, test, and validate human-relevant models at scale, aligning with industry compliance standards.
This startup received a €2.30M seed investment on the 1st of March, 2025. Key investors such as High-Tech Gründerfonds, Martin Ventures, Nidobirds Ventures, Innovationsstarter Fonds, Gilson, and NEDGEX backed the round, showcasing strong confidence in mo:re's potential to transform key aspects of drug development pipelines.
